Viridian Therapeutics, Inc. (VRDN)

Market Cap	1.42B +47.3%
Revenue (ttm)	70.85M +23,359.9%
Net Income	-281.93M
EPS	-3.32
Shares Out	103.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,052,646
Open	14.41
Previous Close	14.23
Day's Range	13.56 - 14.49
52-Week Range	11.76 - 34.29
Beta	1.17
Analysts	Strong Buy
Price Target	35.46 (+158.27%)
Earnings Date	May 7, 2026

About VRDN

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves’ disease and TED. Its portfolio of engineered inhibitors o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 252
• Stock Exchange: NASDAQ
• Ticker Symbol: VRDN
• Website: https://www.viridiantherapeutics.com

Financial Performance

In 2025, Viridian Therapeutics's revenue was $70.85 million, an increase of 23359.93% compared to the previous year's $302,000. Losses were -$281.93 million, 35.2% more than in 2024.

Analyst Summary

According to 14 analysts, the average rating for VRDN stock is "Strong Buy." The 12-month stock price target is $35.46, which is an increase of 158.27% from the latest price.

Price Target

$35.46

(158.27% upside)

Analyst Consensus: Strong Buy